Yvette van Kooyk

This study identifies the CD44-CD206 axis as a glycoimmune checkpoint that promotes immune exclusion in bladder tumours with immature O-glycosylation.

This study shows that reducing sialylation in melanoma enhances classical pathway-mediated complement activation, increasing C3 opsonization and membrane attack complex formation.

This study identifies SIGLEC1 as a mediator of macrophage-CD8+ T cell interactions in melanoma and shows its correlation with response to immune checkpoint blockade.

The paper shows CMAS in melanoma cells correlates with poor survival and reduced response to immunotherapy by altering tumor-immune interactions.

The paper identifies VHH/single-domain antibodies that either block or enhance Siglec-1 ligand binding to sialylated pathogens on dendritic cells.